Amylyx Pharmaceuticals Inc

AMLX

Equity

ISIN US03237H1014 / Valor 115580129

NASDAQ (2025-04-04)

USD 3.43-2.28%

Amylyx Pharmaceuticals Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Amylyx Pharmaceuticals Inc is a biopharmaceutical company focused on developing therapies for neurodegenerative diseases, with a particular focus on amyotrophic lateral sclerosis (ALS) and Alzheimer's disease.

Summarized from source with an LLMView SourceSector: Healthcare

Acquired In-Process R&D

Amylyx Pharmaceuticals Inc reported acquired in-process research and development expenses of $36.2 million for the third quarter of 2024. This marks a significant increase compared to zero for the same period in 2023, primarily due to the acquisition of in-process research and development assets of avexitide.

R&D Expenses

For the third quarter of 2024, Amylyx Pharmaceuticals Inc's research and development expenses were $21.2 million, down from $30.0 million in the same quarter of 2023. The decrease was mainly attributed to reduced clinical expenses and lower payroll and personnel-related costs following a restructuring plan.

SG&A Expenses

Amylyx Pharmaceuticals Inc's selling, general, and administrative expenses for Q3 2024 were $17.8 million, a decrease from $48.7 million in Q3 2023. This reduction was largely due to decreased payroll and personnel-related costs and a decline in consulting and professional services.

Net Loss

The company reported a net loss of $72.7 million, or $1.07 per share, for the third quarter of 2024. This contrasts with a net income of $20.9 million, or $0.30 per diluted share, for the same period in 2023.

Cash Position

As of September 30, 2024, Amylyx Pharmaceuticals Inc had cash, cash equivalents, and marketable securities totaling $234.4 million, compared to $309.8 million as of June 30, 2024. The company anticipates that its cash runway will extend into 2026.

Summarized from source with an LLMView Source

Key figures

31.4%1Y

-75.3%3Y

%5Y

Performance

78.4%1Y

131%3Y

130%5Y

Volatility